Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock


Crinetics announces that it intends to offer and sell, subject to market and other conditions, $400.0 million of shares of its common stock in a proposed underwritten public offering.

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly


Crinetics announces the submission of a New Drug Application to the FDA for its investigational drug, paltusotine, for the treatment of acromegaly.

Crinetics Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to fifteen new non-executive employees.

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences


Crinetics management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference.

Crinetics Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 103,900 shares of its common stock to fifteen new non-executive employees.